Skip to main content

Published locations for FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment

User login

  • Reset your password
  • /content/fda-reapproves-gemtuzumab-ozogamicin-cd33-positive-aml-treatment
  • /hematologynews/article/145979/aml/fda-reapproves-gemtuzumab-ozogamicin-cd33-positive-aml-treatment
  • /oncologypractice/article/145979/aml/fda-reapproves-gemtuzumab-ozogamicin-cd33-positive-aml-treatment
  • /hematology-oncology/article/145979/aml/fda-reapproves-gemtuzumab-ozogamicin-cd33-positive-aml